Table 1 Major phase III clinical studies of target therapy in gastric and esophagogastric junction adenocarcinoma
(see
Notes 3 and 4)
Study
Phase
N
Experimental arm
Control arm OS HR OS Exp OS CON OS ab. diff PFS HR PFS Exp PFS CON PFS ab. diff
First lineToGA (2010) [
8 ]
III
584 Trastuzumab
+^
PF/PX
PF/PX
0.74
13.8
11.1
2.7
0.71
6.7
5.5
1.2
Subgroup: IHC2+ and FISH+/IHC3+
0.65
16.0
11.8
4.2
NR
NR
NR
NR
LOGiC (2016) [
9 ]
III
545 Lapatinib
+
CAPOX
CAPOX
0.91
12.2
10.5
1.7
0.82
6
5.4
0.6
Subgroups
Asian
0.68
16.5
10.9
5.6
Patients <60
years old
0.69
12.9
9.0
3.9
EXPNAD (2013) [
19
]
III
994 Cetuximab
+
PX
PX
1
9.4
10.7
−1.3
1.09
4.4
5.6
−1.2
REAL3 (2013) [
20
]
III
553 Panitumumab
+
EOC EOC
1.37
8.8
11.3
−2.5
1.22
6.0
7.4
−1.4
AVAGAST (2011) [
22
]
III
774 Bevacizumab
+
PX
PX
0.87
12.1
10.1
2.0
0.80
6.7
5.3
1.4
RILOMET-1 (2015) [
41
] III
609 Rilotumumab
+
ECX ECX
1.37
9.6
11.5
−1.9
1.30
5.7
5.7
0
MetGastric (2015) [
42
]
III
562 Onartumumab
+mFOLFOX6
mFOLFOX6 0.82
11
11.3
−0.3
0.90
6.7
6.8
−0.1
Subgroup: MET2+/3+
0.64
11
9.7
1.3
0.79
6.9
5.7
1.2
Second lineRAINBOW (2014) [
26
]
III
665 Ramucirumab
+^
paclitaxel
Paclitaxel
0.81
9.6
7.4
2.2
0.64
4.4
2.9
1.5
GATSBY (2017) [
18
]
II/III
345 TDM-1
Paclitaxel
1.15
7.9
8.6
−0.7
1.13
2.7
2.9
−0.2
TyTAN (2014) [
14
]
III
261 Lapatinib
+^
paclitaxel
Paclitaxel
0.84
11
8.9
2.1
0.85
5.4
4.4
1.0 (continued)